Recent research progress on metabolic syndrome and risk of Parkinson's disease
© 2022 Walter de Gruyter GmbH, Berlin/Boston..
Parkinson's disease (PD) is one of the most widespread neurodegenerative diseases. PD is associated with progressive loss of substantia nigra dopaminergic neurons, including various motor symptoms (e.g., bradykinesia, rigidity, and resting tremor), as well as non-motor symptoms (e.g., cognitive impairment, constipation, fatigue, sleep disturbance, and depression). PD involves multiple biological processes, including mitochondrial or lysosomal dysfunction, oxidative stress, insulin resistance, and neuroinflammation. Metabolic syndrome (MetS), a collection of numerous connected cerebral cardiovascular conditions, is a common and growing public health problem associated with many chronic diseases worldwide. MetS components include central/abdominal obesity, systemic hypertension, diabetes, and atherogenic dyslipidemia. MetS and PD share multiple pathophysiological processes, including insulin resistance, oxidative stress, and chronic inflammation. In recent years, MetS has been linked to an increased risk of PD, according to studies; however, the specific mechanism remains unclear. Researchers also found that some related metabolic therapies are potential therapeutic strategies to prevent and improve PD. This article reviews the epidemiological relationship between components of MetS and the risk of PD and discusses the potentially relevant mechanisms and recent progress of MetS as a risk factor for PD. Furthermore, we conclude that MetS-related therapies are beneficial for the prevention and treatment of PD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Reviews in the neurosciences - 34(2023), 7 vom: 26. Okt., Seite 719-735 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Lin-Yi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Insulin resistance |
|---|
| Anmerkungen: |
Date Completed 05.10.2023 Date Revised 11.10.2023 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1515/revneuro-2022-0093 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349629803 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349629803 | ||
| 003 | DE-627 | ||
| 005 | 20231226043101.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/revneuro-2022-0093 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1165.xml |
| 035 | |a (DE-627)NLM349629803 | ||
| 035 | |a (NLM)36450297 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Lin-Yi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent research progress on metabolic syndrome and risk of Parkinson's disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.10.2023 | ||
| 500 | |a Date Revised 11.10.2023 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Walter de Gruyter GmbH, Berlin/Boston. | ||
| 520 | |a Parkinson's disease (PD) is one of the most widespread neurodegenerative diseases. PD is associated with progressive loss of substantia nigra dopaminergic neurons, including various motor symptoms (e.g., bradykinesia, rigidity, and resting tremor), as well as non-motor symptoms (e.g., cognitive impairment, constipation, fatigue, sleep disturbance, and depression). PD involves multiple biological processes, including mitochondrial or lysosomal dysfunction, oxidative stress, insulin resistance, and neuroinflammation. Metabolic syndrome (MetS), a collection of numerous connected cerebral cardiovascular conditions, is a common and growing public health problem associated with many chronic diseases worldwide. MetS components include central/abdominal obesity, systemic hypertension, diabetes, and atherogenic dyslipidemia. MetS and PD share multiple pathophysiological processes, including insulin resistance, oxidative stress, and chronic inflammation. In recent years, MetS has been linked to an increased risk of PD, according to studies; however, the specific mechanism remains unclear. Researchers also found that some related metabolic therapies are potential therapeutic strategies to prevent and improve PD. This article reviews the epidemiological relationship between components of MetS and the risk of PD and discusses the potentially relevant mechanisms and recent progress of MetS as a risk factor for PD. Furthermore, we conclude that MetS-related therapies are beneficial for the prevention and treatment of PD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Parkinson’s disease | |
| 650 | 4 | |a insulin resistance | |
| 650 | 4 | |a metabolic syndrome | |
| 650 | 4 | |a oxidative stress | |
| 650 | 4 | |a risk factors | |
| 650 | 4 | |a treatment | |
| 700 | 1 | |a Liu, Shu-Fen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhuang, Jian-Long |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Mi-Mi |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Zheng-Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yan-Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiang-Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Chun-Nuan |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Shu |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Li-Chao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Reviews in the neurosciences |d 1987 |g 34(2023), 7 vom: 26. Okt., Seite 719-735 |w (DE-627)NLM074824201 |x 2191-0200 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g number:7 |g day:26 |g month:10 |g pages:719-735 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/revneuro-2022-0093 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2023 |e 7 |b 26 |c 10 |h 719-735 | ||